Intergroup 0144 a phase III rectal surgical adjuvant study of pelvic radiation (XRT) plus 5-FU based chemotherapy (bolus 5-FU before and after PVI + XRT vs PVI before, during, and after XRT vs biochemically modulated bolus 5-FU and XRT): Mature outcome results and pelvic failure analysis
Stephen R. Smalley(Mayo Clinic), Norman Estes(Southern Research Institute), J MARTENSON(Mayo Clinic in Arizona), C. Cripps(Canadian Partnership Against Cancer), Ruth J. Mayer(Research Triangle Park Foundation), J. M. Robertson(Cancer Research UK), Jacqueline Benedetti(University of Illinois Chicago), B FISHER, A.B. Benson(Moog (United States)), Stephen K. Williamson(The University of Kansas Cancer Center)
International Journal of Radiation Oncology*Biology*Physics
September 1, 2004
Cited by 2
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection
|Journal of Clinical Oncology|2012|856
Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype
|PLoS ONE|2012|849
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
|Journal of Clinical Oncology|2016|291
Phase III Trial of Fluorouracil-Based Chemotherapy Regimens Plus Radiotherapy in Postoperative Adjuvant Rectal Cancer: GI INT 0144
|Journal of Clinical Oncology|2006|167